Furthermore, combining anti-VEGF blockade with inhibition of IL-6 plus chemotherapeutic agent doxorubicin in obese mice delayed tumor progression similar to lean mice on VEGF blockade and doxorubicin. Here, VEGFA is linked to neoplasm.